FDA Panel Recommends Approval For CryoCor's Device

A Food and Drug Administration advisory panel recommended that the agency approve CryoCor Inc.'s (CRYO) Cardiac Cryoablation System to correct irregular heartbeats sending the stock price soaring $2.17 to $4.71.